Privately-held biotech Bonti said today that it launched the Lantern clinical program, evaluating its intramuscular neurotoxin injection as a non-opioid pain reliever.
The first clinical trial, Lantern-1, is a Phase II study designed to assess the safety and efficacy of EB-001 in patients undergoing elective breast augmentation.
Get the full story at our sister site, Drug Delivery Business News.
The post Bonti kicks off Ph2 trial for neurotoxin pain-reliever appeared first on MassDevice.
from MassDevice http://ift.tt/2g68OpL
Cap comentari:
Publica un comentari a l'entrada